- 作者：Murat Gö ; k ; Veerle M.H. Coupé ; Johannes Berkhof ; René ; H.M. Verheijen ; Theo J.M. Helmerhorst ; Cornelis J.A. Hogewoning ; Peter J.F. Snijders ; Chris J.L.M. Meijer
- 关键词：Human papillomavirus ; Cervical intraepithelial neoplasia ; Post-treatment CIN ; HPV16 ; HPV18
- 刊名：Gynecologic Oncology
- 出版年：2007
- 期刊代码：295_00908258
- 类别：med
- 出版时间：February 2007
- 卷：104
- 期：2
- 页码：273-275
- 文件大小：121 K
Addition of high-risk human papillomavirus (hrHPV) testing to post-treatment monitoring policies of women treated for high-grade cervical intraepithelial neoplasia (CIN) may improve the effectiveness of detecting recurrent/residual disease. Recent studies have shown that HPV type 16 confers an increased risk of high-grade CIN and cervical cancer. This study aimed to find out whether the post-treatment CIN3 rate is increased in HPV16-positive women treated for CIN3.
Methods.
We included 229 hrHPV-positive women treated for CIN3. HPV typing was performed by GP5+/6+-PCR followed by reverse line blotting on a cervical scrape taken before treatment. HPV typing data were related to the occurrence of post-treatment CIN3 within a median follow-up time of 20.1 months (range 3–85.4 months) following treatment.
Results.
Twenty nine of the 151 (19%) HPV16-positive women versus 6 of the 78 (8%) women with other hrHPV types had recurrent/residual CIN3. Post-treatment CIN3 rate was significantly increased in women with HPV16 compared to those harboring other hrHPV types (p = 0.03). None of the other hrHPV types were associated with higher post-treatment CIN3 rates.
Conclusion.
Women treated for HPV16 containing CIN3 should be monitored more intensively because of their increased risk of post-treatment CIN3. Thus, the HPV genotype should be considered in post-treatment monitoring policies.